UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
October 29, 2001
----------------
(Date of Report)
ENTROPIN, INC.
--------------
(Exact name of registrant as specified in its charter)
Colorado 33-23693 84-1090424
---------------------------- ----------- -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
45926 Oasis Street, Indio, California 92201
-------------------------------------------
(Address of principal executive offices, including zip code)
(760) 775-8333
--------------
(Registrant's telephone number, including area code)
N/A
---
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS.
---------------------
Entropin, Inc. ("Entropin") issued the following press release on
October 17, 2001:
NEWS RELEASE
------------
ENTROPIN EMBARKS ON COMPREHENSIVE INVESTOR RELATIONS PROGRAM
INDIO, Calif. (October 17, 2001) - Entropin, Inc. (NASDAQ: ETOP; ETOPW)
today reported that it has begun a comprehensive Investor Relations
Program. The goal of this campaign is to familiarize the investment
community with the progress Entropin is achieving in the development of
Esterom(R). Esterom(R) is a revolutionary new topical drug which has the
potential to replace other current therapeutics for treating impaired
physical function resulting from painful soft tissue injuries and diseases
- such as tendonitis, bursitis and lower back sprain.
Entropin has begun a series of presentations that will include more than
twenty U.S. cities. Members of Entropin's executive management team will
meet with fund managers, brokers and analysts. The Company is also
conducting an extensive direct mail program to inform the financial
community of the Company's progress.
The Company's presentation is based on publicly available information and
focuses on the unique characteristics of Esterom(R), the protocol design
for the current clinical trial, the Company's scientific, development and
research partners, as well as, Entropin's business strategy and its
development timeline for Esterom(R).
Entropin's President and Chief Executive Officer, Thomas G. Tachovsky,
Ph.D., commented, "Esterom(R) is a revolutionary new product with immense
potential. We are enthusiastic about the anticipated outcome of our
current clinical trial and want to share our story with investors." Dr.
Tachovsky went on to add, "Our goal is to reach a broad audience within the
investment community."
On September 25, 2001, the Company announced that it had begun its current
clinical trial. This Phase II/III Study is a double blind, placebo-
controlled study designed to treat 150 patients for shoulder pain and
disability. Non-placebo patients will receive treatments of 10% Esterom(R)
solution on three consecutive days with a seven-day follow-up period. The
study has clearly defined endpoints and will employ validated measurement
tools to determine the effect of Esterom(R) treatments.
The Company expects enrollment of the 150 patients to take approximately
six months. Entropin has contracted with Medidata Solutions for state-of-
the-art on-line centralized data capture to provide real-time monitoring
and to shorten the time required to analyze the data when the study is
complete. Based on the time required to recruit patients that meet the
study's diagnostic entry criteria, the Company anticipates releasing the
results of this study in the first half of 2002.
2
Entropin, Inc. is a specialty pharmaceutical research and development
company focused on the development of Esterom(R), a revolutionary new
topical product with the potential to replace other current therapeutics
for treating impaired physical function resulting from painful soft tissue
injuries and diseases -- such as tendonitis, bursitis and lower back
sprain.
THIS NEWS RELEASE INCLUDES FORWARD-LOOKING STATEMENTS THAT REFLECT
ENTROPIN'S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND FINANCIAL
PERFORMANCE. THE WORDS "BELIEVE," "EXPECT," "ANTICIPATE," AND SIMILAR
EXPRESSIONS IDENTIFY FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS
ARE SUBJECT TO A VARIETY OF RISKS, UNCERTAINTIES, AND OTHER FACTORS THAT
COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE EXPRESSED IN ANY
SUCH FORWARD-LOOKING STATEMENTS. THESE FACTORS INCLUDE, BUT ARE NOT LIMITED
TO: (1) THE ABILITY TO SUCCESSFULLY COMPLETE DEVELOPMENT AND
COMMERCIALIZATION OF PRODUCTS, INCLUDING THE COST, SCOPE AND RESULTS OF
PRECLINICAL AND CLINICAL TESTING; (2) THE ABILITY TO SUCCESSFULLY COMPLETE
PRODUCT RESEARCH AND FURTHER DEVELOPMENT, INCLUDING PRE-CLINICAL AND
CLINICAL STUDIES; (3) THE TIME, COST AND UNCERTAINTY OF OBTAINING
REGULATORY APPROVALS; (4) THE ABILITY TO OBTAIN SUBSTANTIAL ADDITIONAL
FUNDING; (5) THE ABILITY TO DEVELOP AND COMMERCIALIZE PRODUCTS BEFORE
COMPETITORS; AND (6) OTHER FACTORS DETAILED FROM TIME TO TIME IN FILINGS
WITH THE SECURITIES AND EXCHANGE COMMISSION.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: October 29, 2001 ENTROPIN, INC.
By /s/ THOMAS G. TACHOVSKY
-------------------------------
Thomas G. Tachovsky
President and Chief Executive Officer